The Experts below are selected from a list of 3 Experts worldwide ranked by ideXlab platform

Alan J Bank - One of the best experts on this subject based on the ideXlab platform.

  • carvedilol Lisinopril combination therapy and endothelial function in obese individuals with hypertension
    Journal of Clinical Hypertension, 2012
    Co-Authors: Aaron S Kelly, Michael J Gonzalezcampoy, Kyle Rudser, Harold Katz, Andrea M Metzig, Melissa Thalin, Alan J Bank
    Abstract:

    The authors hypothesized that carvedilol controlled-release Plus Lisinopril combination therapy (C+L) would increase endothelial function and decrease oxidative stress to a greater extent than Hydrochlorothiazide Plus Lisinopril combination therapy (H+L) in obese patients with hypertension. Twenty-five abdominally obese patients (aged 54.4±7.3 years; 14 women) with hypertension/prehypertension were enrolled in a 7-month (two 3-month treatment periods separated by a 1-month washout), randomized, double-blind, controlled, crossover clinical trial comparing C+L vs H+L. Endothelial function, measured by digital reactive hyperemic index (RHI), circulating oxidized low-density lipoprotein (oxLDL), 8-isoprostane, and asymmetric dimethylarginine (ADMA) were obtained at baseline, post-period 1, post-washout, and post-period 2. Analyses were adjusted for baseline measurements by analysis of covariance, with robust variance estimation for confidence intervals and P values. C+L treatment compared to H+L treatment significantly improved RHI (0.74, 95% confidence interval, 0.31–1.19, P =.001). This difference persisted after adjustment for the change in systolic blood pressure. No significant treatment differences were observed for oxLDL, 8-isoprostane, or ADMA. These data provide evidence that independent of blood pressure–lowering, C+L therapy improves endothelial function to a greater extent than H+L therapy. Levels of oxidative stress were not significantly different between treatments, suggesting that other mechanisms may be responsible for the improvement in endothelial function.

Aaron S Kelly - One of the best experts on this subject based on the ideXlab platform.

  • carvedilol Lisinopril combination therapy and endothelial function in obese individuals with hypertension
    Journal of Clinical Hypertension, 2012
    Co-Authors: Aaron S Kelly, Michael J Gonzalezcampoy, Kyle Rudser, Harold Katz, Andrea M Metzig, Melissa Thalin, Alan J Bank
    Abstract:

    The authors hypothesized that carvedilol controlled-release Plus Lisinopril combination therapy (C+L) would increase endothelial function and decrease oxidative stress to a greater extent than Hydrochlorothiazide Plus Lisinopril combination therapy (H+L) in obese patients with hypertension. Twenty-five abdominally obese patients (aged 54.4±7.3 years; 14 women) with hypertension/prehypertension were enrolled in a 7-month (two 3-month treatment periods separated by a 1-month washout), randomized, double-blind, controlled, crossover clinical trial comparing C+L vs H+L. Endothelial function, measured by digital reactive hyperemic index (RHI), circulating oxidized low-density lipoprotein (oxLDL), 8-isoprostane, and asymmetric dimethylarginine (ADMA) were obtained at baseline, post-period 1, post-washout, and post-period 2. Analyses were adjusted for baseline measurements by analysis of covariance, with robust variance estimation for confidence intervals and P values. C+L treatment compared to H+L treatment significantly improved RHI (0.74, 95% confidence interval, 0.31–1.19, P =.001). This difference persisted after adjustment for the change in systolic blood pressure. No significant treatment differences were observed for oxLDL, 8-isoprostane, or ADMA. These data provide evidence that independent of blood pressure–lowering, C+L therapy improves endothelial function to a greater extent than H+L therapy. Levels of oxidative stress were not significantly different between treatments, suggesting that other mechanisms may be responsible for the improvement in endothelial function.

Michael J Gonzalezcampoy - One of the best experts on this subject based on the ideXlab platform.

  • carvedilol Lisinopril combination therapy and endothelial function in obese individuals with hypertension
    Journal of Clinical Hypertension, 2012
    Co-Authors: Aaron S Kelly, Michael J Gonzalezcampoy, Kyle Rudser, Harold Katz, Andrea M Metzig, Melissa Thalin, Alan J Bank
    Abstract:

    The authors hypothesized that carvedilol controlled-release Plus Lisinopril combination therapy (C+L) would increase endothelial function and decrease oxidative stress to a greater extent than Hydrochlorothiazide Plus Lisinopril combination therapy (H+L) in obese patients with hypertension. Twenty-five abdominally obese patients (aged 54.4±7.3 years; 14 women) with hypertension/prehypertension were enrolled in a 7-month (two 3-month treatment periods separated by a 1-month washout), randomized, double-blind, controlled, crossover clinical trial comparing C+L vs H+L. Endothelial function, measured by digital reactive hyperemic index (RHI), circulating oxidized low-density lipoprotein (oxLDL), 8-isoprostane, and asymmetric dimethylarginine (ADMA) were obtained at baseline, post-period 1, post-washout, and post-period 2. Analyses were adjusted for baseline measurements by analysis of covariance, with robust variance estimation for confidence intervals and P values. C+L treatment compared to H+L treatment significantly improved RHI (0.74, 95% confidence interval, 0.31–1.19, P =.001). This difference persisted after adjustment for the change in systolic blood pressure. No significant treatment differences were observed for oxLDL, 8-isoprostane, or ADMA. These data provide evidence that independent of blood pressure–lowering, C+L therapy improves endothelial function to a greater extent than H+L therapy. Levels of oxidative stress were not significantly different between treatments, suggesting that other mechanisms may be responsible for the improvement in endothelial function.

Kyle Rudser - One of the best experts on this subject based on the ideXlab platform.

  • carvedilol Lisinopril combination therapy and endothelial function in obese individuals with hypertension
    Journal of Clinical Hypertension, 2012
    Co-Authors: Aaron S Kelly, Michael J Gonzalezcampoy, Kyle Rudser, Harold Katz, Andrea M Metzig, Melissa Thalin, Alan J Bank
    Abstract:

    The authors hypothesized that carvedilol controlled-release Plus Lisinopril combination therapy (C+L) would increase endothelial function and decrease oxidative stress to a greater extent than Hydrochlorothiazide Plus Lisinopril combination therapy (H+L) in obese patients with hypertension. Twenty-five abdominally obese patients (aged 54.4±7.3 years; 14 women) with hypertension/prehypertension were enrolled in a 7-month (two 3-month treatment periods separated by a 1-month washout), randomized, double-blind, controlled, crossover clinical trial comparing C+L vs H+L. Endothelial function, measured by digital reactive hyperemic index (RHI), circulating oxidized low-density lipoprotein (oxLDL), 8-isoprostane, and asymmetric dimethylarginine (ADMA) were obtained at baseline, post-period 1, post-washout, and post-period 2. Analyses were adjusted for baseline measurements by analysis of covariance, with robust variance estimation for confidence intervals and P values. C+L treatment compared to H+L treatment significantly improved RHI (0.74, 95% confidence interval, 0.31–1.19, P =.001). This difference persisted after adjustment for the change in systolic blood pressure. No significant treatment differences were observed for oxLDL, 8-isoprostane, or ADMA. These data provide evidence that independent of blood pressure–lowering, C+L therapy improves endothelial function to a greater extent than H+L therapy. Levels of oxidative stress were not significantly different between treatments, suggesting that other mechanisms may be responsible for the improvement in endothelial function.

Harold Katz - One of the best experts on this subject based on the ideXlab platform.

  • carvedilol Lisinopril combination therapy and endothelial function in obese individuals with hypertension
    Journal of Clinical Hypertension, 2012
    Co-Authors: Aaron S Kelly, Michael J Gonzalezcampoy, Kyle Rudser, Harold Katz, Andrea M Metzig, Melissa Thalin, Alan J Bank
    Abstract:

    The authors hypothesized that carvedilol controlled-release Plus Lisinopril combination therapy (C+L) would increase endothelial function and decrease oxidative stress to a greater extent than Hydrochlorothiazide Plus Lisinopril combination therapy (H+L) in obese patients with hypertension. Twenty-five abdominally obese patients (aged 54.4±7.3 years; 14 women) with hypertension/prehypertension were enrolled in a 7-month (two 3-month treatment periods separated by a 1-month washout), randomized, double-blind, controlled, crossover clinical trial comparing C+L vs H+L. Endothelial function, measured by digital reactive hyperemic index (RHI), circulating oxidized low-density lipoprotein (oxLDL), 8-isoprostane, and asymmetric dimethylarginine (ADMA) were obtained at baseline, post-period 1, post-washout, and post-period 2. Analyses were adjusted for baseline measurements by analysis of covariance, with robust variance estimation for confidence intervals and P values. C+L treatment compared to H+L treatment significantly improved RHI (0.74, 95% confidence interval, 0.31–1.19, P =.001). This difference persisted after adjustment for the change in systolic blood pressure. No significant treatment differences were observed for oxLDL, 8-isoprostane, or ADMA. These data provide evidence that independent of blood pressure–lowering, C+L therapy improves endothelial function to a greater extent than H+L therapy. Levels of oxidative stress were not significantly different between treatments, suggesting that other mechanisms may be responsible for the improvement in endothelial function.